Characterization of Risk Factors for Genitourinary Infections with Sodium-Glucose Cotransporter-2 Inhibitors.

The incidence of genitourinary infection with SGLT2 inhibitor use was lower than suggested in clinical trials, with lower eGFR and history of genitourinary infection the only identified predictors for increased risk in this population. Genitourinary infection risk should not deter clinicians from recommending or prescribing SGLT2 inhibitor therapy.